Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Mito-LND (Mito-Loidamine) 是一种有口服活性和靶向线粒体的氧化磷酸化抑制剂。它抑制线粒体生物能,刺激活性氧的形成,并诱导肺癌细胞自噬细胞死亡。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 1,080 | 现货 | ||
2 mg | ¥ 1,660 | 现货 | ||
5 mg | ¥ 2,790 | 现货 | ||
10 mg | ¥ 4,150 | 现货 | ||
25 mg | ¥ 6,630 | 现货 | ||
50 mg | ¥ 8,850 | 现货 | ||
100 mg | ¥ 11,900 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 4,230 | 现货 |
产品描述 | Mito-LND (Mito-Loidamine) is an orally active and mitochondria-targeted inhibitor of oxidative phosphorylation. |
体外活性 | Mito-LND inhibits cell growth of H2030BrM3 and A549 cells with IC50 of 0.74 μM and 0.69?μM, respectively. Mito-LND inhibits mitochondrial complex I and II activities with IC50 of 1.2 μM and 2.4?μM, respectively in H2030BrM3 cells. Mito-LND potently induces mitochondrial ROS generation in H2030BrM3 lung cancer cells. Mito-LND decreases the levels of phosphorylated AKT. Mito-LND also decreases the phosphorylation of P70S6K and other energy-sensing proteins in both the parental and metastatic lung cancer cell lines, indicating that Mito-LND specifically downregulates mTOR signaling. |
体内活性 | Mito-LNDtreatment markedly enhanced potency against both lung cancer progression and metastasis. Mito-LND also decreases the rate of growth of A549 tumor xenografts. Mito-LND treatment shows a marked decrease in lung cancer brain metastasis in NOD/SCID mice bearing H2030BrM3 cells. |
别名 | Mito-Loidamine |
分子量 | 801.62 |
分子式 | C43H45BrCl2N3OP |
CAS No. | 2361564-49-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 45 mg/mL(56.14 mM), Sonification is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 1.2475 mL | 6.2374 mL | 12.4747 mL | 31.1868 mL |
5 mM | 0.2495 mL | 1.2475 mL | 2.4949 mL | 6.2374 mL | |
10 mM | 0.1247 mL | 0.6237 mL | 1.2475 mL | 3.1187 mL | |
20 mM | 0.0624 mL | 0.3119 mL | 0.6237 mL | 1.5593 mL | |
50 mM | 0.0249 mL | 0.1247 mL | 0.2495 mL | 0.6237 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Mito-LND 2361564-49-8 Apoptosis Autophagy Immunology/Inflammation Metabolism NF-Κb OXPHOS Reactive Oxygen Species Mitochondrial Metabolism Mito-Lonidamine mTOR Mito-Loidamine p70S6K oxidative MitoLND Inhibitor inhibit mitochondria Mito LND anti-invasive anti-cancer phosphorylation AKT inhibitor